According to a recent report by India Ratings and Research (Ind-Ra), the low-cost and high-value proposition of Indian generic exports offers significant cost advantages to the US healthcare industry. It further noted that the proportion of the US’ contribution to pharma revenue has been steadily declining over the past few years.